Brought to you by 
Sandoz buys Genetic Therapy for $295 million
13 Jul 1999
Executive Summary
In a move to solidify its position in gene therapy, Sandoz will buy Genetic Therapy in a cash offer of $295 million, or $21 per share, a 38% premium to GTI's closing price of $15.25 on 7/7/95.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sandoz buys Genetic Therapy for $295 million
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice